Země: Spojené státy
Jazyk: angličtina
Zdroj: NLM (National Library of Medicine)
NORGESTIMATE (UNII: C291HFX4DY) (NORGESTIMATE - UNII:C291HFX4DY), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)
Naari Pte Limited
PRESCRIPTION DRUG
Norgestimate and ethinyl estradiol tablets USP are indicated for use by females of reproductive potential to prevent pregnancy [see CLINICAL STUDIES ( 14)]. Norgestimate and ethinyl estradiol tablets are contraindicated in females who are known to have or develop the following conditions: • A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: o Smoke, if over age 35 [see BOXED WARNING AND WARNINGS AND PRECAUTIONS ( 5.1)] o Have deep vein thrombosis or pulmonary embolism, now or in the past [see WARNINGS AND PRECAUTIONS ( 5.1)] o Have inherited or acquired hypercoagulopathies [see WARNINGS AND PRECAUTIONS ( 5.1)] o Have cerebrovascular disease [see WARNINGS AND PRECAUTIONS ( 5.1)] o Have coronary artery disease [see WARNINGS AND PREC
Norgestimate and ethinyl estradiol tablets USP (0.25 mg/0.035 mg) are available in a blister card: (NDC 79929-008-05). Each blister card (28 tablets) contains in the following order: • 21 dark blue unscored round tablets debossed with on one side with “14”; the tablet contains 0.25 mg norgestimate and 0.035 mg ethinyl estradiol • 7 white round unscored tablets (non-hormonal placebo) debossed on one side with “11”; the tablet contains inert ingredients Norgestimate and Ethinyl Estradiol Tablets USP, (0.25 mg/0.035 mg) are packaged in a carton (NDC 79929-008-05) containing 3 blister cards. VERIDATE Tablet Dispenser is not applicable for the ANDA product • Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [see USP controlled room temperature]. • Protect from light.
Abbreviated New Drug Application
NORGESTIMATE AND ETHINYL ESTRADIOL- NORGESTIMATE AND ETHINYL ESTRADIOL NAARI PTE LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE NORGESTIMATE AND ETHINYL ESTRADIOL TABLETS USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR NORGESTIMATE AND ETHINYL ESTRADIOL TABLETS USP. NORGESTIMATE AND ETHINYL ESTRADIOL TABLETS USP, FOR ORAL USE INITIAL U.S. APPROVAL: 1989 WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • NORGESTIMATE AND ETHINYL ESTRADIOL TABLET IS CONTRAINDICATED IN WOMEN OVER 35 YEARS OLD WHO SMOKE. ( 4) • CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR EVENTS FROM COMBINATION ORAL CONTRACEPTIVES (COC) USE. ( 4) RECENT MAJOR CHANGES Warnings and Precautions ( 5.11) 12/2021 INDICATIONS AND USAGE Norgestimate and ethinyl estradiol tablets USP are estrogen/progestin COCs, indicated for use by women to prevent pregnancy. ( 1.1) DOSAGE AND ADMINISTRATION • Take one tablet daily by mouth at the same time every day. ( 2.2) • Take tablets in the order directed on the blister. ( 2.2) • Do not skip or delay tablet intake. ( 2.2) DOSAGE FORMS AND STRENGTHS Norgestimate and ethinyl estradiol tablets consist of 28 round, biconvex, coated tablets in the following order ( 3): • 21 blue tablets each containing 0.250 mg norgestimate and 0.035 mg ethinyl estradiol • 7 white tablets (inert) CONTRAINDICATIONS • A high risk of arterial or venous thrombotic diseases ( 4) • Liver tumors or liver disease ( 4) • Undiagnosed abnormal uterine bleeding ( 4) • Pregnancy( 4) • Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive ( 4) • Co-administration with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir ( 4) WARNINGS AND PRECAUTIONS • Thromboembolic Disorders and Other Vascular Problems: Stop norgestimate and ethinyl estradiol tablets if a thrombotic Přečtěte si celý dokument